Home » CHEMGENEX AND STRAGEN CREATE ALLIANCE
CHEMGENEX AND STRAGEN CREATE ALLIANCE
June 29, 2005
ChemGenex Pharmaceuticals, based in Melbourne, Australia and Menlo Park, Calif., and Stragen Pharma, based in Geneva, Switzerland, announced an international alliance to accelerate the clinical development of ChemGenex's lead anti-cancer therapeutic, Ceflatonin. Ceflatonin is currently in a Phase II clinical trial at the M.D. Anderson Cancer Center in Houston, Texas treating chronic myeloid leukemia (CML) patients who are resistant to Gleevec.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20465320&full=1)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct